Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | PRKCI | P41743 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5569174 | 0.98 | GSK3B (0.39) | GSK3BPTPN1P2RX7ALDH1A1KMT2A | |
| SCHEMBL27964366 | 0.81 | PTGS2 (0.36) | P2RX7ALDH1A1KMT2AMAPTMEN1 | |
| SCHEMBL14683977 | 0.79 | P2RX7 (0.34) | P2RX7ALDH1A1KMT2AMAPTKDM4E | |
| SCHEMBL20436419 | 0.78 | LMNA (0.40) | P2RX7ALDH1A1KMT2AMAPTKDM4E | |
| SCHEMBL17205267 | 0.77 | GSK3B (0.39) | GSK3BPTPN1 | |
| SCHEMBL4973075 | 0.76 | GSK3B (0.34) | GSK3BPTPN1ALDH1A1KMT2APRKCI | |
| SCHEMBL5518273 | 0.75 | KDM4E (0.36) | P2RX7ALDH1A1KMT2AMAPTKDM4E | |
| SCHEMBL6170342 | 0.75 | GSK3B (0.41) | GSK3BPTPN1ALDH1A1KMT2AMAPT | |
| SCHEMBL10558381 | 0.75 | GAA (0.35) | P2RX7ALDH1A1KMT2AMAPTMEN1 | |
| SCHEMBL29601119 | 0.75 | RAB9A (0.41) | GSK3BPTPN1P2RX7ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2738163-B1 | AMIDINE COMPOUND OR SALT THEREOF | TAISHO PHARMACEUTICAL CO LTD (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-9045466-B2 | Amidine compound or salt thereof | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-06-02 | — | — | US | disclosed |
| US-9045466-B2 | Amidine compound or salt thereof | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-06-02 | — | — | US | disclosed |
| US-9045466-B2 | Amidine compound or salt thereof | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-06-02 | — | — | US | disclosed |
| US-20140155597-A1 | AMIDINE COMPOUND OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2014-06-05 | — | — | US | disclosed |
| US-20140155597-A1 | AMIDINE COMPOUND OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2014-06-05 | — | — | US | disclosed |
| US-20140155597-A1 | AMIDINE COMPOUND OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2014-06-05 | — | — | US | disclosed |
| EP-2738163-A1 | AMIDINE COMPOUND OR SALT THEREOF | Taisho Pharmaceutical Co., Ltd. (JP) | 2014-06-04 | — | — | EP | disclosed |
| EP-2738163-A1 | AMIDINE COMPOUND OR SALT THEREOF | Taisho Pharmaceutical Co., Ltd. (JP) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013018735-A1 | AMIDINE COMPOUND OR SALT THEREOF | 大正製薬株式会社 (JP) | 2013-02-07 | — | — | WO | disclosed |
| US-20070043083-A1 | Thiazolyl piperidine derivatives | HOFFMANN-LA ROCHE INC. | 2007-02-22 | — | — | US | disclosed |
| WO-2007002126-A1 | ALKYL SULFONAMIDE DERIVATIVES | H. LUNDBECK A/S (DK) | 2007-01-04 | — | — | WO | disclosed |
| US-20060293341-A1 | Alkyl sulfonamide derivatives | H. LUNDBECK A/S (DK) | 2006-12-28 | — | — | US | disclosed |
| EP-1583742-A1 | NOVEL CB 1 RECEPTOUR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-12 | — | — | EP | disclosed |
| EP-1480976-A1 | THIAZOLE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-12-01 | — | — | EP | disclosed |
| US-20040167129-A1 | Novel CB 1 receptor inverse agonists | HOFFMANN-LA ROCHE INC. | 2004-08-26 | — | — | US | disclosed |
| WO-2004060870-A1 | NOVEL CB 1 RECEPTOUR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-22 | — | — | WO | disclosed |
| US-6686381-B2 | COMPOUNDS THAT ANTAGONIZE NEUROPEPTIDE Y AT THE Y5 RECEPTOR SUBTYPE REPRESENT AN APPROACH TO THE TREATMENT OF EATING DISORDERS SUCH AS OBESITY AND HYPERPHAGIA | HOFFMANN-LA ROCHE INC. | 2004-02-03 | — | — | US | disclosed |
| US-20030225141-A1 | THIAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003072577-A1 | THIAZOLE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043083-A1 | Thiazolyl piperidine derivatives | HRH3, HRH4, H1-3 | GSK3B 2584/4885PTPN1 1830/4885P2RX7 145/4885 |
| US-20060293341-A1 | Alkyl sulfonamide derivatives | NPY5R, NPY1R, NPY4R | GSK3B 1701/4885PTPN1 263/4885P2RX7 103/4885 |
| US-20030225141-A1 | THIAZOLE DERIVATIVES | SLC5A1, GPR119, TAS1R1 | GSK3B 2175/4885PTPN1 220/4885P2RX7 3713/4885 |
| US-20040167129-A1 | Novel CB 1 receptor inverse agonists | CNR1, CNR2, ARRB1 | GSK3B 2533/4885PTPN1 991/4885P2RX7 93/4885 |
| US-20140155597-A1 | AMIDINE COMPOUND OR SALT THEREOF | ERG28, ARG1, THEM6 | GSK3B 4722/4885PTPN1 2151/4885P2RX7 3539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.